Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Jerald C. Sadoff"'
Autor:
Hanneke Schuitemaker, Jerald C. Sadoff, Gert Scheper, Jeroen Stoop, Emmanuel Cormier, Pierre Van Damme, Isabel Leroux-Roels, Johan Van Hoof, Anne Marit de Groot, Wim Van Damme, Frank Struyf, Sarah Tete, Carla Truyers, Mathieu Le Gars, Jenny Hendriks, William T. Smith, Murray Kimmel, Dirk Heerwegh, Kristen W. Cohen, Georgi Shukarev, Jan de Hoon, M Juliana McElrath, Macaya Douoguih, Dan H. Barouch, Stephen C De Rosa, Pieter-Jan Berghmans, Kathryn E. Stephenson
Publikováno v:
The New England Journal of Medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
New England Journal of Medicine
NEW ENGLAND JOURNAL OF MEDICINE
The New England journal of medicine
BACKGROUND: Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A candidate vaccine, Ad26.COV2.S, is a recombinan
Autor:
Frank Struyf, Mathieu Le Gars, Ian M. Kaplan, Tochi Anioke, Catherine Jacob-Dolan, Erica N. Borducchi, Katherine McMahan, Macaya Douoguih, Florian Krammer, Sally Shin, Michelle A. Lifton, Abishek Chandrashekar, Joseph P. Nkolola, Lisa H. Tostanoski, David R. Martinez, Aiquan Chang, Jinyan Liu, Paul A. Fields, Kathryn E. Stephenson, Anne Marit de Groot, Jerald C. Sadoff, Harlan Robins, Hanneke Schuitemaker, Dan H. Barouch, Jingyou Yu, Ralph S. Baric, Dirk Heerwegh, Fatima Amanat, Caroline Atyeo, Galit Alter, Johan Van Hoof
Publikováno v:
Nature
The Ad26.COV2.S vaccine1–3 has demonstrated clinical efficacy against symptomatic COVID-19, including against the B.1.351 variant that is partially resistant to neutralizing antibodies1. However, the immunogenicity of this vaccine in humans against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c48aa07cacbb44fbd291d2931e461c0
Autor:
Mo Weijtens, Lauren Peter, Glenda Gray, Katleen Callewaert, Erica N. Borducchi, David C. Montefiori, Thomas B. Campbell, Frank Tomaka, Kathy Mngadi, Fatima Laher, Joseph P. Nkolola, David Jetton, Jenny Hendriks, Roland Zahn, Frances Priddy, Edith Swann, Juliet Mpendo, Sorachai Nitayapan, Karin Feddes-de Boer, Wenjun Li, Stephan Bart, Erica Lazarus, Abishek Chandrashekar, Jennifer Johnson, Frank Wegmann, Steven Nijs, Lindsey R. Baden, Merlin L. Robb, Nigel Garrett, Ludo Lavreys, Galit Alter, Dan H. Barouch, Etienne Karita, Hanneke Schuitemaker, Daniel J. Stieh, Georgia D. Tomaras, Nicole Frahm, M. Juliana McElrath, Danielle van Manen, Zelda Euler, Gregg Lucksinger, Lorenz Scheppler, Hannah Kibuuka, Robert Feldman, Raphaele Roten, Maria G. Pau, Kathryn E. Stephenson, Caroline Borremans, Nelson L. Michael, Punnee Pitisuttithum, Jessica Vreugdenhil, Jeroen Tolboom, Jerald C. Sadoff, Kundai Chinyenze, Bette T. Korber, Julia Hutter
Publikováno v:
Lancet, 392(10143), 232-243. Elsevier Limited
Summary Background More than 1·8 million new cases of HIV-1 infection were diagnosed worldwide in 2016. No licensed prophylactic HIV-1 vaccine exists. A major limitation to date has been the lack of direct comparability between clinical trials and p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6169a5479eb278fd28c754f353bca4e7
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
https://pure.amc.nl/en/publications/evaluation-of-a-mosaic-hiv1-vaccine-in-a-multicentre-randomised-doubleblind-placebocontrolled-phase-12a-clinical-trial-approach-and-in-rhesus-monkeys-nhp-1319(234e01f2-b4e8-4e15-ba68-ebe28532f079).html
Autor:
W. R. Ballou, J. Blood, François Nosten, Jerald C. Sadoff, T. Chongsuphajaissidhi, Nicholas J. White, Dennis E. Kyle, K. H. Webster, Daniel M. Gordon, Pratap Singhasivanon, J. Wittes, Chansuda Wongsrichanalai, D. G. Heppner, Christine Luxemburger
Publikováno v:
Scopus-Elsevier
SummarySeveral years ago the Walter Reed Army Institute of Research (WRAIR) initiated an independent analysis of the candidate malaria blood stage vaccine SPf66. WRAIR contracted for the synthesis and formulation of SPf66 in United States Food and Dr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::57f2242fc3d10d0e6ec1847ed12db48b
https://doi.org/10.1017/s0031182000001463
https://doi.org/10.1017/s0031182000001463
Autor:
Vicky Cárdenas, Romulo Puga, Juan Perez, Jose L. Sanchez, Christian T. Bautista, Robert H. Gilman, Alvaro Gaillour, Rina Meza, Jerald C. Sadoff, Rodolfo E. Begue, David N. Taylor, Peter Echeverria
Publikováno v:
The Journal of Infectious Diseases. 181:1667-1673
The protective efficacy of an oral inactivated whole cell Vibrio cholerae plus recombinant B subunit cholera vaccine was determined against El Tor cholera among Peruvian children and adults (2-65 years old) in a randomized, double-blind manner. Study
Autor:
Jerald C. Sadoff, Edith C. Bougouma, Noelie Henri, Alfred B. Tiono, Souleymane Sanon, Sodiomon B. Sirima, Amidou Diarra, Valerie Brown, Amadou T. Konaté, Edison Wiesken, Alphonse Ouedraogo, Issa Nebie, Isabella Versteege, Désiré Kargougou, Jenny Hendriks, Issiaka Soulama, Nora L. Watson, Espérance Ouédraogo, Adama Gansané, Jean Baptiste Yaro, Youssouf Kaboré, David T. Kangoye, Maria Grazia Pau
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78679 (2013)
PLoS ONE
PLoS ONE
Background Ad35.CS.01 is a pre-erythrocytic malaria candidate vaccine. It is a codon optimized nucleotide sequence representing the P. falciparum circumsporozoite (CS) surface antigen inserted in a replication deficient Adenovirus 35 backbone. A Phas
Autor:
Donald R. Skillman, Richard L. Warren, Herman Schneider, Lillian Van De Verg, Jerald C. Sadoff, Hugh J. Wylie, Alan S. Cross, Katherine A. Schmidt, Carolyn D. Deal
Publikováno v:
Journal of Infectious Diseases. 173:1422-1427
In a human challenge experiment, the infectivity of gonococci with sialylated lipooligosaccharide (LOS) was compared with the infectivity of gonococci with unsialylated LOS. Volunteers were intraurethrally inoculated with approximately 5000 sialylate
Autor:
Thomas L. Hale, Genevieve Losonsky, Karen L. Kotloff, David N. Taylor, Steven S. Wasserman, Myron M. Levine, James P. Nataro, Jerald C. Sadoff
Publikováno v:
Vaccine. 13:1488-1494
In the absence of a definitive immunologic correlate of protection against shigellosis, promising Shigella vaccine candidates have been selected based on their ability to confer resistance against experimental challenge with wild-type Shigella in hea
Autor:
Beattie David, Dallas C. Hack, Andrew Trofa, Tracy Hyman, Trinka S. Coster, Julie Kenner, John Ezzell, John J. Mekalanos, Kevin P. Killeen, Jerald C. Sadoff, David N. Taylor, Arthur Friedlander, Maria H. Sjogren
Publikováno v:
Journal of Infectious Diseases. 170:1518-1523
Vibrio cholerae El Tor strains from Peru, Bangladesh, and Bahrain were attenuated by deletion of a genetic element that encodes virulence factors and RS1. The B subunit of ctx (ctxB) was reintroduced into the recA gene of the deletion mutants, render
Autor:
Ann-Mari Svennerholm, G. Castellares, Bruno Vasquez, César Cabezas, Jose L. Sanchez, Rina Meza, Jerald C. Sadoff, R. E. Begue, David N. Taylor, D. M. Watts
Publikováno v:
The Lancet. 344:1273-1276
The cholera epidemic in South America has reinforced the need for safe and effective oral vaccines. In a randomised, double-blind, placebo-controlled efficacy trial among 1563 Peruvian military recruits we have investigated the protective efficacy of